Lantheus (NASDAQ:LNTH) Shares Up 4.4% – Here’s What Happened

Lantheus Holdings, Inc. (NASDAQ:LNTH)’s stock price shot up 4.4% during trading on Monday . The stock traded as high as $110.98 and last traded at $111.01. 721,991 shares traded hands during mid-day trading, a decline of 21% from the average session volume of 916,695 shares. The stock had previously closed at $106.34.

Analyst Ratings Changes

A number of research firms have recently weighed in on LNTH. Truist Financial lifted their price target on Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a report on Thursday, February 27th. The Goldman Sachs Group started coverage on Lantheus in a research note on Wednesday, December 18th. They set a “buy” rating and a $143.00 target price on the stock. JMP Securities reiterated a “market outperform” rating and set a $112.00 price target on shares of Lantheus in a research report on Tuesday, January 14th. Finally, StockNews.com lowered Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $132.86.

Lantheus Trading Down 3.6 %

The firm has a 50-day moving average price of $91.43 and a 200-day moving average price of $96.86. The company has a market capitalization of $6.91 billion, a price-to-earnings ratio of 16.78 and a beta of 0.38.

Lantheus (NASDAQ:LNTH) last released its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.23). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The firm had revenue of $391.11 million for the quarter, compared to analyst estimates of $376.61 million. Equities research analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Mary Anne Heino sold 53,107 shares of Lantheus stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the transaction, the director now directly owns 440,399 shares in the company, valued at $41,551,645.65. The trade was a 10.76 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director James H. Thrall sold 1,000 shares of the company’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total value of $94,760.00. Following the sale, the director now directly owns 33,207 shares of the company’s stock, valued at approximately $3,146,695.32. This represents a 2.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. State of New Jersey Common Pension Fund D lifted its position in shares of Lantheus by 0.4% in the 4th quarter. State of New Jersey Common Pension Fund D now owns 26,428 shares of the medical equipment provider’s stock valued at $2,364,000 after acquiring an additional 115 shares in the last quarter. Bleakley Financial Group LLC raised its stake in Lantheus by 6.1% during the 4th quarter. Bleakley Financial Group LLC now owns 2,237 shares of the medical equipment provider’s stock valued at $200,000 after purchasing an additional 129 shares during the period. Avantax Advisory Services Inc. lifted its holdings in shares of Lantheus by 5.9% in the fourth quarter. Avantax Advisory Services Inc. now owns 2,382 shares of the medical equipment provider’s stock valued at $213,000 after purchasing an additional 132 shares in the last quarter. Foundry Partners LLC boosted its position in shares of Lantheus by 4.5% in the fourth quarter. Foundry Partners LLC now owns 3,103 shares of the medical equipment provider’s stock worth $278,000 after buying an additional 133 shares during the period. Finally, UMB Bank n.a. grew its holdings in shares of Lantheus by 31.5% during the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock valued at $50,000 after buying an additional 134 shares in the last quarter. 99.06% of the stock is currently owned by institutional investors and hedge funds.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.